Dissolution testing

In the pharmaceutical industry, drug dissolution testing is routinely used to provide critical in vitro drug release information for both quality control purposes, i.e., to assess batch-to-batch consistency of solid oral dosage forms such as tablets, and drug development, i.e., to predict in vivo drug release profiles.[1]


In vitro drug dissolution data generated from dissolution testing experiments can be related to in vivo pharmacokinetic data by means of in vitro-in vivo correlations (IVIVC). A well established predictive IVIVC model can be very helpful for drug formulation design and post-approval manufacturing changes.[2]

The main objective of developing and evaluating an IVIVC is to establish the dissolution test as a surrogate for human studies, as stated by the Food and Drug Administration (FDA). Analytical data from drug dissolution testing are sufficient in many cases to establish safety and efficacy of a drug product without in vivo tests, following minor formulation and manufacturing changes (Qureshi and Shabnam, 2001). Thus, the dissolution testing which is conducted in dissolution apparatus must be able to provide accurate and reproducible results.

Several dissolution apparatuses exist. In United States Pharmacopeia (USP) General Chapter <711> Dissolution, there are four dissolution apparatuses standardized and specified.[3] They are:

• USP Dissolution Apparatus 1 - Basket (37°C)

• USP Dissolution Apparatus 2 - Paddle (37°C)

• USP Dissolution Apparatus 3 - Reciprocating Cylinder (37°C)

• USP Dissolution Apparatus 4 - Flow-Through Cell (37°C)

USP Dissolution Apparatus 2 is the most widely used apparatus among these four.

The performances of dissolution apparatuses are highly dependent on hydrodynamics due to the nature of dissolution testing. The designs of the dissolution apparatuses and the ways of operating dissolution apparatuses have huge impacts on the hydrodynamics, thus the performances. Hydrodynamic studies in dissolution apparatuses were carried out by researchers over the past few years with both experimental methods and numerical modeling such as Computational Fluid Dynamics (CFD). The main target was USP Dissolution Apparatus 2.[1][4][5][6][7][8][9][10] The reason is that many researchers suspect that USP Dissolution Apparatus 2 provides inconsistent and sometimes faulty data.[11][12][13][14][15][16][17] The hydrodynamic studies of USP Dissolution Apparatus 2 mentioned above clearly showed that it does have intrinsic hydrodynamic issues which could result in problems. In 2005, Professor Piero Armenante from New Jersey Institute of Technology (NJIT) and Professor Fernando Muzzio from Rutgers University submitted a technical report to the FDA.[18] In this technical report, the intrinsic hydrodynamic issues with USP Dissolution Apparatus 2 based on the research findings of Armenante's group and Muzzio's group were discussed.

More recently, hydrodynamic studies were conducted in USP Dissolution Apparatus 4.[19][20][21]

References

  1. 1 2 Bai, G., Wang, Y., Armenante, P. M., “Velocity profiles and shear strain rate variability in the USP Dissolution Testing Apparatus 2 at Different Impeller Agitation Speeds, ” International Journal of Pharmaceutics, 403 (1-2), Pages 1-14, 2011
  2. ↑ Kortejärvi H, Malkki J, Marvola M, Urtti A, Yliperttula M, Pajunen P., "Level A In Vitro-In Vivo Correlation (IVIVC) Model with Bayesian Approach to Formulation Series". J Pharm Sci. 95 (7), Pages 1595-1605, 2006.
  3. ↑ United States Pharmacopeia 34/National Formulary 29, 2011.
  4. ↑ Bai, G., Armenante, P. M., “Hydrodynamics, Mass transfer and Dissolution Effects Induced by Tablet Location during Dissolution Testing,” Journal of Pharmaceutical Sciences, Volume 98, Issue 4, Pages 1511-1531, 2009
  5. ↑ Bai, G., Armenante, P. M., “ Velocity Distribution and Shear Rate Variability Resulting from Changes in the Impeller Location in the USP Dissolution Testing Apparatus II, “ Pharmaceutical Research, Volume 25, Issue 2, Pages 320-336, 2008
  6. ↑ Bai, G., Armenante, P. M., Plank, R. V., “Experimental and Computational Determination of Blend Time in USP Dissolution Testing Apparatus II,” Journal of Pharmaceutical Sciences, Volume 96, Issue 11, Pages 3072-3086, 2007.
  7. ↑ Bai, G., Armenante, P. M., Plank, R. V., Gentzler, M., Ford, K. and Harmon P., “Hydrodynamic Investigation of USP Dissolution Test Apparatus II,” Journal of Pharmaceutical Sciences, Volume 96, Issue 9, Pages 2327-2349, 2007.
  8. ↑ Kukura J., Baxter JL., Muzzio FJ., "Shear distribution and variability in the USP Apparatus 2 under turbulent conditions". Int J Pharm. 279 (1-2), Pages 9–17, 2004.
  9. ↑ Baxter JL, Kukura J, Muzzio FJ. "Hydrodynamics-induced variability in the USP Apparatus II Dissolution Test". Int J Pharmaceutics 292 (1-2), Pages 17–28, 2005
  10. ↑ McCarthy L., Bradley G., Sexton J., Corrigan O., Healy AM., "Computational fluid dynamics modeling of the paddle dissolution apparatus: Agitation rate mixing patterns and fluid velocities". AAPS Pharm Sci Tech 5 (2), 2004.
  11. ↑ Cox DC., Furman WB., Thornton LK., 1983. Systematic error associated with Apparatus 2 of the USP Dissolution Test III: Limitation of Calibrators and the USP Suitability Test. J Pharm Sci. 72 (8), 910– 913.
  12. ↑ Cox DC., Furman WB., 1982. Systematic error associated with Apparatus 2 of the USP dissolution test I: Effects of physical alignment of the dissolution apparatus. J Pharm Sci 71 (4), 451–452.
  13. ↑ Moore TW., Hamilton JF., Kerner CM., 1995. Dissolution testing: Limitation of USP prednisone and salicylic acid calibrator tablets. Pharmacopeial Forum 21 (5), 1387–1396.
  14. ↑ Costa P, Lobo JMS . 2001 . Influence of dissolution medium agitation on release profiles of sustainedrelease tablets. Drug Devel Ind Pharm 27 (8), 811–817.
  15. ↑ Qureshi SA., McGilveray IJ., 1999. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur J Pharm Sci. 7 (3), 249-258
  16. ↑ Qureshi SA., Shabnam J., 2001. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Euro J Pharm Sci. 12 (3),271–276.
  17. ↑ Mauger J., Ballard J., Brockson R., De S., Gray V., Robinson D., 2003. Intrinsic dissolution performance of the USP dissolution apparatus 2 (rotating paddle) using modified salicylic acid calibration tablets: Proof of principle. Dissol Technol 10(3), 6–15.
  18. ↑
  19. ↑ Kakhi, M.,"Mathematical modeling of the fluid dynamics in the flow-through cell",International Journal of Pharmaceutics, 376 (1-2), pp. 22-40, 2009
  20. ↑ Kakhi, M.,"Classification of the flow regimes in the flow-through cell", European Journal of Pharmaceutical Sciences, 37 (5), pp. 531-544, 2009
  21. ↑ D'Arcy, D.M., Liu, B., Bradley, G., Healy, A.M., Corrigan, O.I.,"Hydrodynamic and species transfer simulations in the USP 4 dissolution apparatus: Considerations for dissolution in a low velocity pulsing flow", Pharmaceutical Research 27 (2), pp. 246-258, 2010
This article is issued from Wikipedia - version of the Tuesday, May 27, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.